EU drug regulators have agreed to review Cerepro, a gene therapy for brain cancer developed by Ark Therapeutics. Ark has presented data that Cerepro can almost double the expected survival times of brain cancer victims.The therapy works by stimulating an enzyme that kills cancer cells.
- read this press release [1] for more information
Links:
[1] http://www.biotech-intelligence.com/html/html/3bf3bda827336ce1e53d9961ab1e1cb3.html